Rhythm Pharmaceuticals Inc  

(Public, NASDAQ:RYTM)   Watch this stock  
Find more results for RYTM
27.00
+1.20 (4.65%)
Nov 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 25.52 - 27.62
52 week 21.38 - 33.81
Open 25.80
Vol / Avg. 131,587.00/199,557.00
Mkt cap 736.67M
P/E     -
Div/yield     -
EPS -1.24
Shares 27.28M
Beta     -
Inst. own 0%

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -81.55% -104.29%
Return on average equity -112.03% -
Employees 15 -
CDP Score - -

Address

500 Boylston St Fl 11
BOSTON, MA 02116-3740
United States - Map
+1-857-2644280 (Phone)
+1-857-2644299 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.

Officers and directors

David P. Meeker M.D. Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Keith Gottesdiener M.D. President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Hunter C. Smith Chief Financial Officer, Treasurer
Age: 49
Bio & Compensation  - Reuters
Lex H.T. Van der Ploeg Ph.D. Chief Scientific Officer
Age: 63
Bio & Compensation  - Reuters
Nithya Desikan Chief Commercial Officer
Age: 38
Bio & Compensation  - Reuters
Fred T. Fiedorek M.D. Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Neil Exter Independent Director
Age: 58
Bio & Compensation  - Reuters
Todd Foley Independent Director
Age: 45
Bio & Compensation  - Reuters
Christophe R. Jean Independent Director
Age: 61
Bio & Compensation  - Reuters
Edward T. Mathers Independent Director
Age: 57
Bio & Compensation  - Reuters